Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer
Brain Disorder
Explore 23 assets in Brain Disorder →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Charite University, Berlin, Germany
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04970355CT.gov Efficacy of Erenumab in Chronic Cluster Headache | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer (this asset) | Charite University, Berlin, Germany | P2 | B · 57 |
| Galantamine Hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | B |
| Donanemab | Eli Lilly and Company | P3 | B |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | B |
| Fremanezumab | Hospital Clínico Universitario de Valladolid | P4 | B |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | B |
| Tocilizumab | Zhujiang Hospital | P3 | B |
| Levodopa | Merck Sharp & Dohme LLC | P2 | B |
| Physiologic Sodium Chloride Solution | Zhujiang Hospital | P3 | B |
+33 more in the Brain Disorder cohort
Other indications for Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Migraine Disorder | — | P4 | BBB · 74 |
| Headache Disorder | — | P4 | BB · 65 |
| Tinnitus | — | P4 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Galantamine HydrobromideJohnson & Johnson Pharmaceutical Research & Development, L.L.C.B
- DonanemabEli Lilly and CompanyB
- Live Combined BifidobacteriumBeijing Friendship HospitalB
- FremanezumabHospital Clínico Universitario de ValladolidB
- Live Combined Bifidobacterium,Lactobacillus And Enterococcus CapsulesBeijing Friendship HospitalB
Citation
Floatz Terminal. Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer in Brain Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-anti-human-calcitonin-gene-related-peptide-receptor-human-monoclonal-heavy-chain-disulfide-with-human-monoclonal-light-chain-dimer-brain-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →